Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 2011TranscriptionOpen Access

Inhibiting eukaryotic transcription. Which compound to choose? How to evaluate its activity?

View Full Paper
Ask AI
Bookmark
Share

Authors

OBOlivier BensaudeCentre National de la Recherche Scientifique

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Olivier Bensaude (2011) studied this question.

synapsesocial.com/papers/69daab95615cc0c8eaa3cacdhttps://doi.org/10.4161/trns.2.3.16172
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Transcription-dependent colocalization of the U1, U2, U4/U6, and U5 snRNPs in coiled bodies1992 · 405 citations
  2. 2Actinomycin D: Renewed RNA Synthesis after Removal from Mammalian Cells1971 · 25 citations
  3. 3Actinomycin D Stimulates the Transcription of rRNA Minigenes Transfected into Mouse Cells1995 · 39 citations
  4. 4The Transcription-Dependent Dissociation of P-TEFb-HEXIM1-7SK RNA Relies upon Formation of hnRNP-7SK RNA Complexes2007 · 105 citations
  5. 5Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease2007 · 236 citations